Patents by Inventor Susan Ashwell

Susan Ashwell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
    Patent number: 10807976
    Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where Y1, X1, X2, Y2, W1, W2, W3, and R1-R5 are described herein.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: October 20, 2020
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, Jr., Justin Andrew Caravella, Wei Lu
  • INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1)
    Publication number: 20200297717
    Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.
    Type: Application
    Filed: June 4, 2020
    Publication date: September 24, 2020
    Inventors: Patrick F. Kelly, Susan Ashwell
  • PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS
    Publication number: 20200223822
    Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, U, W1, W2, W3, R1-R6, and R9 are described herein.
    Type: Application
    Filed: December 12, 2019
    Publication date: July 16, 2020
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, JR., Justin Andrew Caravella, Wei Lu
  • FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS
    Publication number: 20200115343
    Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, B, U, V, Z, W1, W2, W3, and R1-R6 are described herein.
    Type: Application
    Filed: December 12, 2019
    Publication date: April 16, 2020
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, JR., Justin Andrew Caravella, Wei Lu
  • INHIBITING MUTANT IDH-1
    Publication number: 20200108060
    Abstract: Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).
    Type: Application
    Filed: November 25, 2019
    Publication date: April 9, 2020
    Inventors: Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Susan Ashwell, Blythe Thomson
  • Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
    Patent number: 10577329
    Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, B, U, V, Z, W1, W2, W3, and R1-R6 are described herein.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: March 3, 2020
    Assignee: Forma Therapeutics, Inc.
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, Jr., Justin Andrew Caravella, Wei Lu
  • Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
    Patent number: 10550098
    Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, U, W1, W2, W3, R1-R6, and R9 are described herein.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: February 4, 2020
    Assignee: Forma Therapeutics, Inc.
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, Jr., Justin Andrew Caravella, Wei Lu
  • Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
    Patent number: 10550099
    Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, B, W1, W2, W3, and R1-R6 are described herein.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: February 4, 2020
    Assignee: Forma Therapeutics, Inc.
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, Jr., Justin Andrew Caravella, Wei Lu
  • QUINOLINONE FIVE-MEMBERED HETEROCYCLIC COMPOUNDS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS
    Publication number: 20200010464
    Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where Y1, X1, X2, Y2, W1, W2, W3, and R1-R5 are described herein.
    Type: Application
    Filed: July 22, 2019
    Publication date: January 9, 2020
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, JR., Justin Andrew Caravella, Wei Lu
  • INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1)
    Publication number: 20190350921
    Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.
    Type: Application
    Filed: June 4, 2019
    Publication date: November 21, 2019
    Applicant: FORMA Therapeutics, Inc.
    Inventor: Susan Ashwell
  • INHIBITING MUTANT IDH-1
    Publication number: 20190350919
    Abstract: Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).
    Type: Application
    Filed: May 16, 2019
    Publication date: November 21, 2019
    Inventors: Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Susan Ashwell, Blythe Thomson
  • Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
    Patent number: 10414752
    Abstract: The application relates to an inhibitor of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula (I-13):
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: September 17, 2019
    Assignee: Forma Therapeutics, Inc.
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, Jr., Justin Andrew Caravella, Wei Lu
  • Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
    Patent number: 10407419
    Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: (I) where Y1, X1, X2, Y2, W1, W2, W3, and R1-R5 are described herein.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: September 10, 2019
    Assignee: Forma Therapeutics, Inc.
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, Jr., Justin Andrew Caravella, Wei Lu
  • QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS
    Publication number: 20190263779
    Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, B, W1, W2, W3, and R1-R6 are described herein.
    Type: Application
    Filed: March 1, 2019
    Publication date: August 29, 2019
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, JR., Justin Andrew Caravella, Wei Lu
  • PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS
    Publication number: 20190263778
    Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, U, W1, W2, W3, R1-R6, and R9 are described herein.
    Type: Application
    Filed: March 1, 2019
    Publication date: August 29, 2019
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, JR., Justin Andrew Caravella, Wei Lu
  • PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS
    Publication number: 20190210970
    Abstract: The invention relates to methods of reducing the level of 2-hydroxyglutarate in cells by administration of an inhibitor of mutant isocitrate dehydrogenase-1.
    Type: Application
    Filed: December 28, 2018
    Publication date: July 11, 2019
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, JR., Justin Andrew Caravella, Wei Lu
  • QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS
    Publication number: 20190210995
    Abstract: The invention relates to methods of reducing the level of 2-hydroxyglutarate in cells by administration of an inhibitor of mutant isocitrate dehydrogenase-1.
    Type: Application
    Filed: December 28, 2018
    Publication date: July 11, 2019
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, JR., Justin Andrew Caravella, Wei Lu
  • FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS
    Publication number: 20190202790
    Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, B, U, V, Z, W1, W2, W3, and R1-R6 are described herein.
    Type: Application
    Filed: March 12, 2019
    Publication date: July 4, 2019
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, JR., Justin Andrew Caravella, Wei Lu
  • Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
    Patent number: 10294206
    Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula (I) where A, B, U, V, Z, W1, W2, W3, and R1-R6 are described herein.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: May 21, 2019
    Assignee: FORMA TM2, INC.
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, Jr., Justin Andrew Caravella, Wei Lu
  • PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS
    Publication number: 20190135781
    Abstract: The invention relates to methods of reducing the level of 2-hydroxyglutarate in cells by administration of an inhibitor of mutant isocitrate dehydrogenase-1.
    Type: Application
    Filed: December 28, 2018
    Publication date: May 9, 2019
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, Jr., Justin Andrew Caravella, Wei Lu